Merck Sharp + Dohme Corp.

Other

Children's Medical Center Corporation

Merck + Co., Inc.

Harvard College

Nuchem Pharmaceuticals Inc.

Ion Pharmaceuticals, Inc.

Merck Sharp & Dhome Corp.

Ying-Duo Gao

Amjad Ali

Adel M Moussa

Scott D Edmondson

Jose Alberto Halperin

Minghua Sun

Yesh P Sachdeva

Carlo Brugnara

Sung-Sau So

Alan W Hruza

Rongze Kuang

Lihu Yang

Akio Kanatani

Takehiro Fukami

Santhosh Francis Neelamkavil

Anthony K Ogawa

Wanying Sun

Masaki Ihara

Zhuyan Guo

Ann E Weber

Younong Yu

Rajan Anand

Andrew William Stamford

Joseph A Kozlowski

Tesfaye Biftu

Suresh B Singh

Ravi P Nargund

Hao Wu

Wensheng Yu

Dong-Ming Shen

Kathleen M Rupprecht

Wallace T Ashton

Jianming Bao

Zhicai Wu

Jian Liu

Charles G Caldwell

Sherman Tim Waddell

Danqing D Feng

Ping Liu

Robert K Baker

Ronald M Kim

John S Debenham

Cheng Zhu

Xin Gu

Harry R Chobanian

Alan C Cheng

Linus S Lin

Linda L Chang

Yan Guo

Xiaolei Gao

Blaise S Lippa

Richard John Lombardy

John J Clifford

Reem M Haidar

Eugene W Kelleher

Heather N Taft

Weiguo Liu

Eric Mertz

Douglas J MacNeil

Yasuyuki Ishii

Emile M Bellott

Takahiro Fukuroda

Nancy R Morin

Rudolf Fluckiger

Heping Wu

Mark Froimowitz

Yeon-Hee Lim

Yu Jiang

Jiayi Xu

Nancy J Kevin

Jacqueline D Hicks

Jiafang He

Remond Moningka

Linda Brockunier

Shouwu Miao

Wei Zhou

Chundao Yang

Joseph Leslie Duffy

Zhiqiang Zhao

Maria L Garcia

Dexi Yang

Lan Wei

Tingting Yu

Shilan Liu

Gregory J Kaczorowski

Deyou Sha

Sobhana Babu Boga

Thomas A Bara

Chunsing Li

Hongjian Wang

Jan Antoinette C Romero

Oleg B Selyutin

Bart Harper

Yi Zang

Meng Yang

Deodialsingh Guiadeen

Zahid Hussain

Rudrajit Mal

Marc D Chioda

Matthew Lombardo

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Plasma kallikrein inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein. 

Factor XIA inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. 

Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. 

Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators

The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Pyrazole carboxamides of structural formula I are selective inhibitors of the 11&#x3b2;-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.

Pyrazole carboxamides as inhibitors of 11-&#x3b2;-hydroxysteroid dehydrogenase-1

The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Growing community of inventors

Holmdel, NJ, United States of America

Ying-Duo Gao